FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Galante Joseph C						2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ]									k all app Direc	licable)	10% Owner		
(Last) (First) (Middle) 2525 WEST END AVENUE SUITE 950					3. Date of Earliest Transaction (Month/Day/Year) 06/10/2020									below		below			
(Street) NASHVILLE TN 37203				If Amendment, Date of C				f Original Filed (Month/Da			//Year) 6. Ind Line) X		,		rson				
(City)	(SI	te) (Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
D				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securi Benefi Owned		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) c	r P	rice		ed ction(s) 8 and 4)		(Instr. 4)	
Common Stock				06/12/				P		225(1)	A	1	\$3.37	20	),992	D			
Common Stock				06/19/2020				P		375(1)	A \$		\$3.41	21,367		D			
Common Stock				06/26/2020				P		375(1)	375 <sup>(1)</sup> A		\$3.37	21,742		D			
Common Stock				07/02/2020				P		300(1)	A	1	\$3.34	22	2,042	D			
Common Stock				07/10/2020				P		375(1)	A	1	\$3.31	22	2,417	D			
Common Stock				07/17/2020				P		375(1)	A	:	\$3.29	22	2,792	D			
Common Stock				07/24/2020				P		375(1)	A	:	\$3.33	23	3,167	D			
Common Stock				07/31/2020				P		375(1)	A	:	\$3.26	23,542		D			
Common Stock				08/07/2020				P		375(1)	A	!	\$3.42	23,917		D			
Common Stock				08/14/2020				P		375(1)	A	!	\$3.44	24,292		D			
Common Stock				08/21/2020				P		375(1)	A	!	\$3.35		1,667	D			
Common Stock 08/26/					2020				P		225(1)	A	;	\$3.29	24,892		D		
		Т	able II -	Derivati (e.g., pu	ve Se its. ca	curit	ies <i>i</i>	Acqui	ired, C optior	oispo	osed of, o	or Bei	nefic curit	cially (	Owne	t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	) if any		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exerci Expiration Da (Month/Day/Yo		sable and te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. I De Sei (In:	Price of rivative curity str. 5)	∕e derivative	Ownersh Form: Direct (D) or Indirect (I) (Instr.	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numl of Share	ber					
Explanation	of Respon	SAS.																	

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.

## Remarks:

Joseph C. Galante by /s/ Michael Bonner as attorney-

08/28/2020

in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).